Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial-Reference-Cited by-同舟云学术

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Published:2016-04 Issue:4 Volume:27 Page:619-624
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gebhart G.,Lamberts L.E.,Wimana Z.,Garcia C.,Emonts P.,Ameye L.,Stroobants S.,Huizing M.,Aftimos P.,Tol J.,Oyen W.J.G.,Vugts D.J.,Hoekstra O.S.,Schröder C.P.,Menke-van der Houven van Oordt C.W.,Guiot T.,Brouwers A.H.,Awada A.,de Vries E.G.E.,Flamen P.

Funder

Jules Bordet Institute

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/4/619/19446546/mdv577.pdf

Reference19 articles.

1. Trastuzumab emtansine for HER2-positive advanced breast cancer;Verma;N Engl J Med,2012

2. Antimitotic activity of the potent tumor inhibitor maytansine;Remillard;Science,1975

3. Trastuzumab emtansine: mechanisms of action and drug resistance;Barok;Breast Cancer Res,2014